Kane Biotech Announces Q2 Earnings Release and Inaugural Business Update Video
August 14 2019 - 5:55AM
Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane
Biotech”), a biotechnology company engaged in the research,
development and commercialization of technologies and products that
prevent and remove microbial biofilms, today announced that they
will release second quarter fiscal 2019 earnings on Wednesday,
August 21st after market close. The company is pleased to announce
that they will be hosting their first-ever business update in lieu
of an earnings conference call this quarter. The business update
video will feature presentations from several members of Kane’s
team and will go live on September 10th at 4:30pm EST.
Both the Q2 earnings release and the business update video will
be available on Kane’s investor site at
https://ir.kanebiotech.com/press-releases.
“We have been very successful and have seen great progress with
both our Animal Health and Human Health businesses. We continue to
engage with several new partners and distributors in order to grow
sales, expand into new markets and grow our product portfolios. I
look forward to shedding more light on these recent progressions as
well as on what we have planned for the months to come,” stated
Marc Edwards, Chief Executive Officer at Kane Biotech.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research,
development and commercialization of technologies and products that
prevent and remove microbial biofilms. The Corporation has a
portfolio of biotechnologies, intellectual property (56 patents and
patents pending, trade secrets and trademarks) and products
developed by the Corporation’s own biofilm research expertise and
acquired from leading research institutions. StrixNB(TM),
DispersinB(R), Aledex(R), bluestem(TM), AloSera(TM), coactiv+(TM)
and Kane(R) are trademarks of Kane Biotech Inc. The Corporation is
listed on the TSX Venture Exchange under the symbol "KNE".
For more information, please visit
www.kanebiotech.com, or contact:
Marc EdwardsChief Executive OfficerKane Biotech Inc.+1 (514)
910-6991medwards@kanebiotech.com
Ray DupuisChief Financial OfficerKane Biotech Inc.+1 (204)
298-2200rdupuis@kanebiotech.com
Joe GreenUS. Investor RelationsEdison Inc.+1 (646)
653-7030jgreen@edisongroup.com
Laine YonkerUS. Investor RelationsEdison Inc.+1 (646) 653
7035lyonker@edisongroup.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Caution Regarding Forward-Looking
Information
This press release contains certain statements regarding Kane
Biotech Inc. that constitute forward-looking information under
applicable securities law. These statements reflect management’s
current beliefs and are based on information currently available to
management. Certain material factors or assumptions are applied in
making forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
These risks and uncertainties include, but are not limited to,
risks relating to the Company’s: (a) financial condition, including
lack of significant revenues to date and reliance on equity and
other financing; (b) business, including its early stage of
development, government regulation, market acceptance for its
products, rapid technological change and dependence on key
personnel; (c) intellectual property including the ability of the
Company to protect its intellectual property and dependence on its
strategic partners; and (d) capital structure, including its lack
of dividends on its common shares, volatility of the market price
of its common shares and public company costs. Further information
about these and other risks and uncertainties can be found in the
disclosure documents filed by the Company with applicable
securities regulatory authorities, available at www.sedar.com. The
Company cautions that the foregoing list of factors that may affect
future results is not exhaustive.
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Apr 2024 to May 2024
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From May 2023 to May 2024